Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 14/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 12/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1497299 | 0.87 | ADORA2B (0.58) | ADORA2BADORA2AADORA3ADORA1 | |
| SCHEMBL1001281 | 0.86 | ADORA2B (0.61) | ADORA2BADORA2AADORA3ADORA1 | |
| SCHEMBL1497226 | 0.86 | ADORA2B (0.59) | ADORA2BADORA2AADORA3ADORA1 | |
| SCHEMBL1497212 | 0.79 | ADORA2B (0.49) | ADORA2BADORA2AADORA3ADORA1 | |
| SCHEMBL27865795 | 0.79 | ADORA2A (0.41) | ADORA2BADORA2AADORA3ADORA1 | |
| SCHEMBL1003792 | 0.78 | ADORA2B (0.62) | ADORA2BADORA2AADORA3ADORA1 | |
| SCHEMBL1001313 | 0.78 | ADORA2B (0.49) | ADORA2BADORA2AADORA3ADORA1 | |
| SCHEMBL1497240 | 0.77 | ADORA2B (0.54) | ADORA2BADORA2AADORA3ADORA1 | |
| SCHEMBL1497167 | 0.77 | ADORA2B (0.54) | ADORA2BADORA2AADORA3ADORA1 | |
| SCHEMBL1497249 | 0.77 | ADORA2B (0.62) | ADORA2BADORA2AADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029143-B1 | SUBSTITUTED 8-[6-AMINO-3-PYRIDYL]XANTHINES | DOGWOOD PHARMACEUTICALS INC (US) | 2015-07-08 | — | — | EP | disclosed |
| US-8258142-B2 | Substituted 8-[6-amino-3-pyridyl]xanthines | DOGWOOD PHARMACEUTICALS, INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-8258142-B2 | Substituted 8-[6-amino-3-pyridyl]xanthines | DOGWOOD PHARMACEUTICALS, INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-8258142-B2 | Substituted 8-[6-amino-3-pyridyl]xanthines | DOGWOOD PHARMACEUTICALS, INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-8193200-B2 | administering a substituted 8-(3-pyridyl)-xanthine; ulcerative colitis; Crohn's disease | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193200-B2 | administering a substituted 8-(3-pyridyl)-xanthine; ulcerative colitis; Crohn's disease | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193200-B2 | administering a substituted 8-(3-pyridyl)-xanthine; ulcerative colitis; Crohn's disease | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-06-05 | — | — | US | disclosed |
| US-20110082139-A1 | SUBSTITUTED 8-[6-AMINO-3-PYRIDYL]XANTHINES | ALLERGAN SALES, LLC | 2011-04-07 | — | — | US | disclosed |
| US-20110082139-A1 | SUBSTITUTED 8-[6-AMINO-3-PYRIDYL]XANTHINES | ALLERGAN SALES, LLC | 2011-04-07 | — | — | US | disclosed |
| US-20110082139-A1 | SUBSTITUTED 8-[6-AMINO-3-PYRIDYL]XANTHINES | ALLERGAN SALES, LLC | 2011-04-07 | — | — | US | disclosed |
| US-7875608-B2 | selective antagonists of A2B adenosine receptors; 6-Chloro-N-[5-(1-cyclopropyl-2,6-dioxo-3-propyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-pyridin-2-yl]-N-(2-pyridin-2-yl-ethyl)-nicotinamide; for treating asthma, diarrhea, insulin resistance, and diabetic retinopathy | ADENOSINE THERAPEUTICS, LLC | 2011-01-25 | — | — | US | disclosed |
| US-20090163491-A1 | SUBSTITUTED 8-[6-AMINO-3PYRIDYL]XANTHINES | ADENOSINE THERAPEUTICS, LTD. | 2009-06-25 | — | — | US | disclosed |
| US-20090163491-A1 | SUBSTITUTED 8-[6-AMINO-3PYRIDYL]XANTHINES | ADENOSINE THERAPEUTICS, LTD. | 2009-06-25 | — | — | US | disclosed |
| US-20090163491-A1 | SUBSTITUTED 8-[6-AMINO-3PYRIDYL]XANTHINES | ADENOSINE THERAPEUTICS, LTD. | 2009-06-25 | — | — | US | disclosed |
| US-20080176845-A1 | Antagonists of A2B adenosine receptors for treatment of inflammatory bowel disease | EMORY UNIVERSITY | 2008-07-24 | — | — | US | disclosed |
| US-20080176845-A1 | Antagonists of A2B adenosine receptors for treatment of inflammatory bowel disease | EMORY UNIVERSITY | 2008-07-24 | — | — | US | disclosed |
| US-20080176845-A1 | Antagonists of A2B adenosine receptors for treatment of inflammatory bowel disease | EMORY UNIVERSITY | 2008-07-24 | — | — | US | disclosed |
| US-20080004292-A1 | Substituted 8-[6-amino-3-pyridyl]xanthines | ALLERGAN SALES, LLC | 2008-01-03 | — | — | US | disclosed |
| US-20080004292-A1 | Substituted 8-[6-amino-3-pyridyl]xanthines | ALLERGAN SALES, LLC | 2008-01-03 | — | — | US | disclosed |
| US-20080004292-A1 | Substituted 8-[6-amino-3-pyridyl]xanthines | ALLERGAN SALES, LLC | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163491-A1 | SUBSTITUTED 8-[6-AMINO-3PYRIDYL]XANTHINES | ADORA2B, ADORA2A, ADORA3 | ADORA2B 1/4885ADORA2A 2/4885ADORA3 3/4885 |
| US-20110082139-A1 | SUBSTITUTED 8-[6-AMINO-3-PYRIDYL]XANTHINES | ADORA2B, ADORA2A, ADORA3 | ADORA2B 1/4885ADORA2A 2/4885ADORA3 3/4885 |
| US-20080004292-A1 | Substituted 8-[6-amino-3-pyridyl]xanthines | ADORA2B, ADORA2A, ADORA3 | ADORA2B 1/4885ADORA2A 2/4885ADORA3 3/4885 |
| US-20080176845-A1 | Antagonists of A2B adenosine receptors for treatment of inflammatory bowel disease | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA2A 2/4885ADORA3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.